EPO联合同步放化疗治疗局部晚期非小细胞肺癌的疗效观察

徐朝久 赵景胜 陈超英 龙剑 丁文信 吴红花 梁静 张金花 周豪

【摘要】 目的 观察促红细胞生成素（EPO）联合同步放化疗治疗局部晚期非小细胞肺癌（LANSCLC）患者的临床疗效。

方法 采用前瞻性研究，纳入2018年1月至2020年1月收治的局部晚期非小细胞肺癌患者89例作为研究对象。根据治疗方式的不同分为研究组（n=46）与对照组（n=43），对照组仅行同步放化疗，研究组采用EPO联合同步放化疗。比较两组患者治疗后Hb的变化、疗效、生存情况及不良反应情况。

结果 治疗后4周两组患者的Hb比较，差异有统计学意义（P<0.001）。研究组的客观缓解率（ORR）为84.78%，明显高于对照组的62.79%（P<0.05）;研究组无进展生存期（PFS）优于对照组（P<0.05）;两组患者总生存率及不良反应发生情况比较，差异无统计学意义（P>0.05）。

结论 EPO联合同步放化疗治疗局部晚期非小细胞肺癌患者，能够保持患者的Hb水平，提高近期疗效，延长生存时间，且不良反应少，安全可靠，值得临床推广应用。

【关键词】 促红细胞生成素;局部晚期非小细胞肺癌;同步放化疗;生存情况

中图分类号：R683    文献标志码：A   DOI：10.3969/j.issn.1003-1383.2021.12.007

【Abstract】 Objective To observe the clinical efficacy of erythropoietin（EPO） combined with concurrent chemoradiotherapy in patients with locally advanced non-small-cell lung cancer （LANSCLC）.

Methods A prospective study was conducted in 89 patients with LANSCLC admitted to hospital from January 2018 to January 2020.According to different treatment methods， the patients were divided into study group （n=46） and control group （n=43）. The control group only received concurrent chemoradiotherapy， and the study group received EPO combined with concurrent chemoradiotherapy. And then， the Hb changes， efficacy， survival and adverse reactions of the two groups were compared after treatment.

Results 4 weeks after treatment， the difference of Hb between the two groups was statistically significant （P<0.001）. The objective response rate （ORR） of the study group was 84.78%， which was significantly higher than that of the control group （62.79%）（P<0.05）. The progression-free survival （PFS） of the study group was better than that of the control group （P<0.05）; There was no statistically significant difference in the overall survival rate and adverse reactions between the two groups （P>0.05）.

Conclusion EPO combined with concurrent chemoradiotherapy for patients with locally advanced non-small-cell lung cancer can maintain patients' Hb levels， improve short-term curative effects， prolong survival time with fewer adverse reactions， which is safe and reliable， and thus is worthy of clinical application.

【Key words】 EPO; LANSCLC; concurrent chemoradiotherapy; survival

肺癌是临床上较为常见的恶性肿瘤之一，在我国城市人口恶性肿瘤死亡病因中居于第一，多数患者确诊时已为局部晚期非小细胞肺癌（locally advanced non-small-cell lung cancer，LANSCLC），同步放化疗为其主要治疗手段[1]。贫血是肺癌患者常见并发症之一，可导致患者出现乏力、嗜睡、呼吸困难等症状，直接影响患者的生存质量，还可引起肿瘤组织的贫血性乏氧，而乏氧影响放化疗的疗效，降低生存期[2]。纠正贫血有望改善患者的生存质量，提高肿瘤对于放射治疗和化学治疗的敏感性，从而提高疗效[3]。……